תוצאות חיפוש - Yue Shentu

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

    Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes מאת Gary Meininger, Russell Scott, Maria Alba, Yue Shentu, Edmund Luo, Himal Amin, Michael J. Davies, Keith D. Kaufman, Barry J. Goldstein

    יצא לאור 2011
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  2. 2
    Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024

    Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024 מאת Charu Aggarwal, Delvys Rodríguez‐Abreu, Enriqueta Felip, Enric Carcereny, Maya Gottfried, Thomas Wehler, Myung‐Ju Ahn, Marisa Dolled‐Filhart, J. Zhang, Yue Shentu, Reshma Rangwala, Bilal Piperdi, Paul Baas

    יצא לאור 2016
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  3. 3
    Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

    Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer מאת Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A. Leiby, Gregory M. Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R. Brahmer

    יצא לאור 2016
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  4. 4
    LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy

    LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy מאת Roy S. Herbst, D.-W. Kim, Enriqueta Felip, Jose Luis Pérez‐Gracia, E.B. Garon, Ji‐Youn Han, Julian R. Molina, J.-H. Kim, R. Gervais, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, E. Im, Paul Baas

    יצא לאור 2015
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  5. 5
    Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010

    Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010 מאת Roy S. Herbst, Paul Baas, Dong‐Wook Kim, Enriqueta Felip, Jose Luis Pérez‐Gracia, J. Y. Han, Juan Pablo Molina, Jae‐Hun Kim, Catherine Dubos Arvis, M-J. Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Yue Shentu, Gregory M. Lubiniecki, E.B. Garon

    יצא לאור 2016
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  6. 6
    PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment

    PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment מאת Roy S. Herbst, Paul Baas, Jose Luis Pérez‐Gracia, Enriqueta Felip, Dong‐Wan Kim, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Veerle Surmont, Gilberto de Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled‐Filhart, Ellie Im, Edward B. Garon

    יצא לאור 2016
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  7. 7
    P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment

    P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment מאת Roy S. Herbst, Paul Baas, Jose Luis Pérez‐Gracia, Enriqueta Felip, Dong‐Wan Kim, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Veerle Surmont, Gilberto de Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled‐Filhart, Ellie Im, Edward B. Garon

    יצא לאור 2016
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  8. 8
    Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

    Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial מאת Roy S. Herbst, Paul Baas, Jose Luis Pérez‐Gracia, Enriqueta Felip, Dong‐Wook Kim, Ji‐Youn Han, Julian R. Molina, Jee Hyun Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Veerle Surmont, Gilberto de Castro, Marcelo Garrido, Yue Shentu, Kenneth Emancipator, Ayman Samkari, Erin Jensen, Gregory M. Lubiniecki, Edward B. Garon

    יצא לאור 2019
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:

כלי חיפוש: